Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.3%

2 terminated out of 47 trials

Success Rate

89.5%

+3.0% vs benchmark

Late-Stage Pipeline

19%

9 trials in Phase 3/4

Results Transparency

35%

6 of 17 completed with results

Key Signals

6 with results89% success

Data Visualizations

Phase Distribution

35Total
Not Applicable (11)
P 1 (6)
P 2 (9)
P 3 (8)
P 4 (1)

Trial Status

Completed17
Recruiting12
Unknown9
Active Not Recruiting4
Not Yet Recruiting2
Terminated2

Trial Success Rate

89.5%

Benchmark: 86.5%

Based on 17 completed trials

Clinical Trials (47)

Showing 20 of 20 trials
NCT07004582Recruiting

Lab Research Using Mini-tumors to Study Prostate Cancer Treatments

NCT05848011Phase 2Completed

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT06970847Phase 3Recruiting

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

NCT05036226Phase 1RecruitingPrimary

COAST Therapy in Advanced Solid Tumors and Prostate Cancer

NCT07485881Not Yet Recruiting

18F-PSMA PET/CT Versus CT Alone in Assessment of Prostatic Cancer Patients

NCT06957691Phase 2Recruiting

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

NCT07410494Phase 1Recruiting

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

NCT03553602Phase 1TerminatedPrimary

HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer

NCT07131956Recruiting

Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy

NCT01857037Not ApplicableCompletedPrimary

Post-radiation Prostate Cancer Local Recurrences: Detection With Histoscanning™ and MRI

NCT04742361Phase 3Completed

Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

NCT02562131Active Not RecruitingPrimary

PET-MR-PSA Prostate Cancer Recidive Study

NCT02974075Not ApplicableCompletedPrimary

Salvage Lymph Node Dissection in Prostate Cancer Patients With Recurrence After Radical Prostatectomy

NCT04011410Phase 2CompletedPrimary

Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer

NCT06922929Phase 3Not Yet RecruitingPrimary

A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment

NCT05384002Completed

An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum

NCT04428203Phase 1CompletedPrimary

Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer

NCT06508567Not ApplicableRecruitingPrimary

Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era

NCT02560181Not ApplicableActive Not RecruitingPrimary

Pilot Study of Whole Gland Salvage HDR Prostate Brachytherapy for Locally Recurrent Prostate Cancer

NCT04312191Not ApplicableWithdrawn

Using Meditation for Oncology Anxiety

Scroll to load more

Research Network

Activity Timeline